Taysha Gene Therapies, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TSHA research report →
Range $13 – $15
Price Chart
About the company
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS).
- CEO
- Sean Nolan
- IPO
- 2020
- Employees
- 99
- HQ
- Dallas, TX, US
Get TickerSpark's AI analysis on TSHA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.21B
- P/E
- -8.65
- Fwd P/E
- 10.59
- PEG
- 0.42
- P/S
- 220.33
- P/B
- 4.23
- EV/EBITDA
- -5.41
- Div Yield
- 0.00%
- Gross Margin
- 89.17%
- Op Margin
- -2935.41%
- Net Margin
- -2844.63%
- ROE
- -51.87%
- ROIC
- -38.96%
Latest fiscal year · YoY change
- Revenue
- $9.77M+17.3%
- Gross Profit
- $9.77M+17.3%
- Op Income
- $-110,498,000
- Net Income
- $-108,995,000-22.1%
- EPS
- $-0.34+5.6%
- OCF Growth
- -14.6%
- FCF Growth
- -15.0%
- 52W High
- $7.30
- 52W Low
- $3.46
- 50D MA
- $4.35
- 200D MA
- $5.28
- Beta
- 1.17
- RSI (14)
- 35
- Avg Volume
- 3.59M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Taysha said Q3 was a strong execution quarter, with TSHA-102 clearing the acute safety window in all treated patients, PPQ manufacturing completed, and cash runway extending into the second half of 2028.· November 12, 2026
- All 33 TSHA-102-treated patients cleared the acute post-dosing safety monitoring period, with no severe treatment-related serious adverse events or dose-limiting toxicities reported as of the November 2026 cutoff.
- The company completed its BLA-enabling PPQ manufacturing campaign, and said process parameters, analytical results, and comparability met predefined specifications for commercial product.
- Management is targeting a first-half-2027 update with top-line data from the REVEAL pivotal six-month interim analysis and FDA feedback on the BLA pathway.
- Taysha said it expects current cash resources of $422.8 million to fund operations and capital needs into the second half of 2028.
- The company is also planning to nominate an additional CNS gene therapy candidate and begin preclinical work in the first half of 2027.
Taysha did not report revenue. Research and development expense was $28.8 million for the third quarter of 2026, up from $25.7 million a year ago; general and administrative expense was $13.1 million, up from $8.3 million. Net loss was $39.1 million, or $0.10 per share, versus a net loss of $32.7 million, or $0.09 per share, in the prior-year quarter. Cash and cash equivalents were $422.8 million at September 30, 2026, and management said that cash should support planned operating expenses and capital requirements into the second half of 2028. The company reiterated a potential path to BLA submission based on either the six-month interim or the 12-month pivotal data, with FDA feedback expected in the first half of 2027.
Sean Nolan framed the quarter as one of strong execution across clinical, manufacturing, and commercial readiness. He emphasized that the completion of dosing and the acute safety window, plus the PPQ manufacturing milestone, strengthen the case for a potential BLA submission and future commercialization of TSHA-102. His tone was confident and forward-looking, repeatedly stressing a potential first-to-market advantage if the six-month data support filing.
Kamran Alam focused on the expense build tied to late-stage development and launch preparation. R&D rose to $28.8 million, driven mainly by clinical expenses in REVEAL and ASPIRE and higher headcount, while G&A increased to $13.1 million on compensation, consulting, and commercial readiness costs. He also highlighted the $422.8 million cash balance and said the company’s current resources should last into the second half of 2028.
Analysts pressed management on whether a six-month dataset would be enough for filing and how FDA would view precedent, and management said the agency will likely look at the totality of evidence, including long-term Part A durability, safety updates, and secondary endpoints. They also confirmed they expect to share the 12-month data later even if they file sooner. Other questions centered on the planned new CNS program, PPQ/CMC alignment with recent FDA guidance, and commercial readiness; management said the PPQ campaign was completed at the commercial Harmans facility and that the company is well aligned with FDA expectations, while also saying payer discussions have been constructive and early launch preparation is well advanced.
The strongest bull case from the call is that TSHA-102 has now treated 33 patients with no severe treatment-related SAEs or dose-limiting toxicities, and management believes the safety profile remains favorable. The company also says it has the manufacturing, regulatory, and commercial infrastructure in place to move quickly if the six-month interim data are compelling, with a possible BLA path and cash runway into 2028.
The key risk is still regulatory and clinical: management is asking FDA to accept a six-month filing approach that it says would be precedent-setting, so approval of that pathway is not assured. The call also showed ongoing spend growth, with both R&D and G&A higher year over year, and the company remains dependent on upcoming interim data and FDA feedback to validate the program’s path forward.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 84.5%
- Shares Outstanding
- 324.86M
- Float Shares
- 274.55M
of shares held by institutions
216 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 30.44M | ▲ 6.88M |
| Goldman Sachs Group Inc | 25.12M | ▲ 2.40M |
| Avoro Capital Advisors LLC | 23.89M | 0 |
| Blackrock, Inc. | 22.65M | ▲ 1.96M |
| Vestal Point Capital, LP | 18.05M | ▼ 1.37M |
| Morgan Stanley | 15.72M | ▼ 764.74K |
| Rtw Investments, LP | 13.56M | 0 |
| Fmr LLC | 13.56M | ▲ 222.55K |
| Vanguard Group Inc | 13.27M | ▲ 418.19K |
| Vanguard Capital Management LLC | 12.54M | ▲ 61.47K |
| State Street Corp | 11.38M | ▼ 41.21K |
| Siren, L.L.C. | 9.85M | 0 |
Held by 257 ETFs
Biggest fund positions in TSHA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 10, 26 | Nagendran Sukumar | sell | 200,000 |
| Jun 1, 26 | Stalfort John A III | other | 21,335 |
| Jun 1, 26 | Stalfort John A III | other | 42,671 |
| Jun 1, 26 | Donenberg Phillip B. | other | 21,335 |
| Jun 1, 26 | Donenberg Phillip B. | other | 42,671 |
| Jun 1, 26 | Long Alison S | other | 21,335 |
| Jun 1, 26 | Long Alison S | other | 42,671 |
| Jun 1, 26 | Sepp-Lorenzino Laura | other | 21,335 |
| Jun 1, 26 | Sepp-Lorenzino Laura | other | 42,671 |
| Apr 10, 26 | Nagendran Sukumar | other | 19,021 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TSHA coverage
Recent articles, reports, and earnings notes.
No research on TSHA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TSHA report →Taysha Gene Therapies, Inc. (TSHA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Taysha Gene Therapies Q3 Earnings Call Highlights
marketbeat.com · Nov 12
Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Nov 12
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 6
Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
globenewswire.com · Nov 5
Taysha Gene Therapies (NASDAQ:TSHA) Hits New 52-Week Low – Time to Sell?
defenseworld.net · Oct 16
Taysha Gene Therapies (NASDAQ:TSHA) versus MediWound (NASDAQ:MDWD) Head to Head Analysis
defenseworld.net · Oct 9
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Oct 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.